Literature DB >> 16820243

Natural IgM antibodies: the orphaned molecules in immune surveillance.

H Peter Vollmers1, Stephanie Brändlein.   

Abstract

Natural IgM antibodies are typical victims of prejudices which originated in the mid 80 s. Over the years, these molecules were considered as the pariahs among the immune competent molecules and their characteristic properties, like low affinity, cross-reactivity and pentameric structure, were assessed as useless, difficult, nebulous, etc. Today, mainly based on a few scientists' persistent work and the key discoveries on innate immune recognition, natural IgM antibodies are "back on stage". Their role in the immune response against bacteria, viruses, fungi and possibly modified self-components as well as in therapy and diagnosis of malignancies is accepted. All the so far negatively judged features are seen in a different light, e.g. low affinity seems to be good for function and does not exclude specificity, and cross-reactivity is no longer judged as unspecific, but instead as a very economic way of immune recognition. And at last, with the use of natural IgM antibodies, a new field of tumor-specific targets has been encountered, the carbo-neo-epitopes. Therefore, by having learned from nature, the renaissance of natural IgM antibodies opens a new area of cancer therapeutics and diagnostics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820243     DOI: 10.1016/j.addr.2005.08.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  23 in total

Review 1.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

2.  The human IgM pentamer is a mushroom-shaped molecule with a flexural bias.

Authors:  Daniel M Czajkowsky; Zhifeng Shao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

Review 3.  Characteristics of natural antibody-secreting cells.

Authors:  Hannah P Savage; Nicole Baumgarth
Journal:  Ann N Y Acad Sci       Date:  2015-06-23       Impact factor: 5.691

4.  A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.

Authors:  Sivasubramanian Baskar; Jessica M Suschak; Ivan Samija; Ramaprasad Srinivasan; Richard W Childs; Steven Z Pavletic; Michael R Bishop; Christoph Rader
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

5.  Natural IgM is produced by CD5- plasma cells that occupy a distinct survival niche in bone marrow.

Authors:  Alexander E Reynolds; Masayuki Kuraoka; Garnett Kelsoe
Journal:  J Immunol       Date:  2014-11-26       Impact factor: 5.422

6.  Presence of a neo-epitope and absence of amyloid beta and tau protein in degenerative hippocampal granules of aged mice.

Authors:  Gemma Manich; Jaume del Valle; Itsaso Cabezón; Antoni Camins; Mercè Pallàs; Carme Pelegrí; Jordi Vilaplana
Journal:  Age (Dordr)       Date:  2013-07-19

7.  Expression and glycoengineering of functionally active heteromultimeric IgM in plants.

Authors:  Andreas Loos; Clemens Gruber; Friedrich Altmann; Ulrich Mehofer; Frank Hensel; Melanie Grandits; Chris Oostenbrink; Gerhard Stadlmayr; Paul G Furtmüller; Herta Steinkellner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

Review 8.  Function, structure and therapeutic potential of complement C5a receptors.

Authors:  P N Monk; A-M Scola; P Madala; D P Fairlie
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

9.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

Review 10.  Fc-fusion proteins: new developments and future perspectives.

Authors:  Daniel M Czajkowsky; Jun Hu; Zhifeng Shao; Richard J Pleass
Journal:  EMBO Mol Med       Date:  2012-07-26       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.